Search

Search Constraints

You searched for: Author/Creator Wolter, Pascal

Search Results

1. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. (September 2018)

2. Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. (July 2020)

4. The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study. Issue 4 (August 2018)

5. Prospective evaluation of hypogonadism in male metastatic renal cell carcinoma patients treated with targeted therapies. Issue 3 (4th May 2019)

6. ABCG2 Polymorphism rs2231142 and hypothyroidism in metastatic renal cell carcinoma patients treated with sunitinib. Issue 3 (4th May 2019)

7. Prognostic factors in second-line targeted therapy for metastatic clear-cell renal cell carcinoma after progression on an anti-vascular endothelial growth factor receptor tyrosine kinase inhibitor. (3rd March 2016)

8. Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. (May 2021)

9. A randomized, open‐label clinical trial of tasisulam sodium versus paclitaxel as second‐line treatment in patients with metastatic melanoma. Issue 13 (26th March 2014)

10. Improving lymph node characterization in staging malignant lymphoma using first‐order ADC texture analysis from whole‐body diffusion‐weighted MRI. Issue 4 (14th April 2018)